Healthcare Oct 20, 2021 09:19 AM (GMT+8) · EqualOcean
Yiouda health learned on the 20th that Shenzhen Kangyuan Jiuyuan Biotechnology Co., Ltd. (hereinafter referred to as Kangyuan Jiuyuan) announced the completion of a round of financing of tens of millions of yuan, which was led by China capital, shared investment, Chengdu Tianfu Sanjiang Asset Management Co., Ltd., Lei meiruis venture capital and Jianyi (Chaoshan capital) as the financial adviser of this round. It is reported that this round of financing funds will be mainly used for ind application of jy108 double anti drugs under Kangyuan Jiuyuan, as well as early research and development of new projects, team expansion, preparation of pilot sites, etc. Jy108 is the product pipeline with the fastest progress in Kangyuan's long-term research products. It is the first peg bispecific linker double antibody to treat autoimmune diseases. Founded in 2018, Kangyuan is an innovative antibody drug R & D enterprise focusing on cancer treatment and autoimmune chronic inflammatory diseases, and is committed to developing platform technology of differentiated technology with clinical advantages. At present, Kangyuan has been developing product pipelines for a long time, including dual antibody, dual antibody ADC, etc.